Specifically, PFD, an FDA‐approved clinically wonder drug for the treatment of idiopathic pulmonary fibrosis, was first introduced to inhibit TGF‐β1 and its downstream signals, thereby reducing collagen deposition and remodeling stiff ECM to become soft. Here, TGFB1 is linked to pulmonary fibrosis.